Top Markets
Coin of the day
Cardiol Therapeutics Inc. Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc.

CRDL
Rangering i aksjer #17188
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company,... Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
Aksjekurs
$2.20
Sist synkronisert: 2026-09-01
Markedsverdi
$253.81M
Endring (1 dag)
10.29%
Endring (1 år)
99.67%
Land
CA
Handel Cardiol Therapeutics Inc. (CRDL)

Kategori

Inntekter for Cardiol Therapeutics Inc. (CRDL)
Inntekter i 2026 TTM: 0
Ifølge Cardiol Therapeutics Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Cardiol Therapeutics Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter